PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette’s syndrome

N Turjanski, G V Sawle, E D Playford, R Weeks, A A Lammerstma, A J Lees, D J Brooks

Abstract
Dysfunction of the dopaminergic pathway has been postulated to underlie the symptomatology of Tourette’s syndrome. Presynaptic functional integrity of dopaminergic terminals was assessed with \(^{18}F\)-dopa PET in 10 patients with Tourette’s syndrome, three of whom were drug free and seven of whom were on neuroleptic treatment. Dopamine D\(_2\) receptor site density was measured with \(^{11}C\)-raclopride PET in a further group of five drug free patients with Tourette’s syndrome. Mean caudate and putamen \(^{18}F\)-dopa influx constants were similar in patients with Tourette’s syndrome and controls, and there was no difference in striatal \(^{18}F\)-dopa uptake between the treated and untreated Tourette’s syndrome groups. Mean caudate and putamen \(^{11}C\)-raclopride binding potentials in patients with Tourette’s syndrome were also similar to control values. The findings suggest that striatal metabolism of exogenous levodopa and the density of striatal D\(_2\) receptors are both normal in patients with Tourette’s syndrome and that Tourette’s syndrome does not arise from a primary dysfunction of dopaminergic terminals.

(3 Neurology Psychiatry 1994;57:688–692)

Gilles de la Tourette’s syndrome is a common disorder, extremely socially disabling in its severest forms. Despite this, little is known about its pathology. It is characterised by simple and complex motor and vocal tics and associated behavioural manifestations such as depression and obsessive-compulsive disorders. It is possible that obsessive behaviour or multiple tics in isolation may represent an incomplete form of this condition. Earlier hypotheses that Tourette’s syndrome had a psychiatric origin have now been replaced by the suggestion that it results from a biochemical disturbance, possibly involving the basal ganglia. There is circumstantial evidence implicating several neurotransmitters in the pathogenesis of this syndrome, including the dopaminergic, noradrenergic, serotonergic, cholinergic, GABAergic, and opioid systems. In particular, dysfunction of the dopaminergic pathway has been postulated to play a central part in the pathogenesis of Tourette’s syndrome. This dopamine hypothesis is based on the following clinical observations: (1) tics usually respond to dopamine receptor antagonists (neuroleptics) and dopamine depleting agents (reserpine, tetrabenazine). (2) Exacerbations of tics have been reported in patients with Tourette’s syndrome exposed to dopamine reuptake inhibitors such as cocaine, and to amphetamines. (3) Neuroleptic withdrawal can lead to tics.

There is also pathological evidence supporting dysfunction of dopaminergic transmission in Tourette’s syndrome. Baseline concentrations of dopamine metabolites have been reported to be reduced in the CSF of patients with Tourette’s syndrome. Postmortem studies with [\(^{3}H\)]mazindol found increased dopamine re-uptake site density in striatum from patients with Tourette’s syndrome.

To help clarify whether dopaminergic dysfunction underlies Tourette’s syndrome, we have assessed the functional integrity of the presynaptic and postsynaptic dopaminergic system with the PET tracers \(^{18}F\)-dopa and \(^{11}C\)-raclopride. The striatal uptake and storage of \(^{18}F\)-dopa reflects the activity of aromatic amino acid decarboxylase and subsequent accumulation in the vesicles located in the presynaptic dopaminergic terminals, whereas \(^{11}C\)-raclopride is a selective reversible D\(_2\) receptor antagonist and its uptake reflects D\(_2\) site binding potential.

Patients and methods

Patients
Fifteen patients with Tourette’s syndrome were recruited for this study from the movement disorder clinics at the National Hospital of Neurology and Neurosurgery, Queen Square and Charing Cross Hospital, London. Fourteen patients with Tourette’s syndrome satisfied DSM-III-R criteria for Tourette’s syndrome and the other had multiple tic disease. Eight had not been given neuroleptic drugs, or had been off medication at least three months before PET. Preliminary data for six of these patients have been previously reported.

Patients studied with \(^{18}F\)-dopa PET
Ten patients were studied with \(^{18}F\)-dopa PET. Their mean age at the time of PET was 30 (range 18–48) years, and at disease onset it was 6 (2–13) years. Seven patients (five men, two women), were taking neuroleptic drugs at the time of PET. Three male patients had not been treated with drugs; two had Tourette’s...
syndrome and one had multiple tic disease. Table 1 summarises patient details and neuroleptic drugs.

The patients’ data were compared with a group of 34 control subjects, mean age 58 (range 20–77), and with a subgroup of seven age matched controls, mean age 30 (range 20–55) years.

**Patients studied with **11C-raclopride PET**

Five men with Tourette’s syndrome were studied with **11C-raclopride; three had not received drugs, two ceased neuroleptic treatment at least three months before PET, one of them had not received neuroleptics for at least three years before this study. Their mean age when studied was 33 (range 18–46) years, and disease onset occurred at a mean age of 8 (range 5–12) years. One of these patients was also studied with **18F-dopa PET. Table 2 gives the patients’ details.

The findings were compared with those of nine control subjects, mean age 50 (range 24–74) years. The data from patients with Tourette’s syndrome were also compared with a subgroup of five age matched controls, mean age 36 (range 24–57) years.

The ethics committee of the Royal Postgraduate Medical School, Hammersmith Hospital, approved this study. Permission to give **18F-dopa and **11C-raclopride was obtained from the Administration of Radioactive Substances Advisory Committee of the UK. All subjects gave written informed consent.

**METHODS**

**PET procedure**

The PET was performed on a CTI 931–08/12 scanner at the MRC Cyclotron Unit, Hammersmith Hospital, London, UK. The reconstructed spatial resolution of this scanner, for 15 simultaneously acquired slices, is 7·0 x 8·5 x 8·5 mm (full width half maximum).

A thermoplastic head mould was made for each subject to gently immobilise the head while in the scanner. Patients were aligned with the orbitomeatal line parallel to the detector rings. A 10 minute transmission scan was collected with an external 68Ga/68Ge retractable ring source to correct for tissue attenuation of emitted radiation.

All medication was withdrawn for at least 12 hours before the PET. On the morning of the study, patients ate a light breakfast. One hour before **18F-dopa PET, they received an oral dose of 100 mg carbipoda, a peripheral dopa decarboxylase blocker.

**18F-dopa—**A mean dose of 123 (SD 41) MBq of **18F-dopa in 5 ml of normal saline (mean specific activity 6·0 MBq/μmol) was given by intravenous infusion over two minutes. Scanning began at the start of tracer infusion with collection of 25 serial time frames, increasing in duration from one to five minutes over a study period of 94 minutes.

**11C-raclopride—**A mean dose of 329(SD 61)

### Table 1 Details of patients with Tourette’s syndrome studied with **18F-dopa PET**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Onset (y)</th>
<th>Simple tics</th>
<th>Complex tics</th>
<th>Obsessions/compulsions</th>
<th>Current drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Motor</td>
<td>Vocal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 M</td>
<td>48</td>
<td>4</td>
<td></td>
<td>Generalised</td>
<td>Throat clearing, barking, shuffling</td>
<td>Jumping, Coprolalia, Echolalia</td>
<td>Checking, Chlorprothixene</td>
</tr>
<tr>
<td>2 F</td>
<td>24</td>
<td>9</td>
<td></td>
<td>Generalised</td>
<td>Sniffing, grunting, barking, shuffling</td>
<td>Self injury, stamping</td>
<td>Echolalia, Complex rituals, checking</td>
</tr>
<tr>
<td>3 F</td>
<td>19</td>
<td>3</td>
<td></td>
<td>Generalised</td>
<td>Sniffing, barking, throat clearing</td>
<td>Bending legs</td>
<td>None, Checking rituals, counting rituals</td>
</tr>
<tr>
<td>4 M</td>
<td>18</td>
<td>13</td>
<td></td>
<td>Generalised</td>
<td>Generalised</td>
<td>Facial gestures, touching self, turning</td>
<td>Facial gestures, turning self</td>
</tr>
<tr>
<td>5 M</td>
<td>29</td>
<td>2</td>
<td></td>
<td>Generalised</td>
<td>Sniffing, grunting</td>
<td>Jumping, knee bends, stamping</td>
<td>Echolalia, coprolalia</td>
</tr>
<tr>
<td>6 M</td>
<td>29</td>
<td>5</td>
<td>Head</td>
<td>Barking, grunting</td>
<td>Shouting</td>
<td>Turning, self injury</td>
<td>Coprolalia</td>
</tr>
<tr>
<td>7 M</td>
<td>46</td>
<td>7</td>
<td>Head</td>
<td>Shouting</td>
<td>Generalised</td>
<td>Coughing, sneezing</td>
<td>Coprolalia</td>
</tr>
<tr>
<td>8 M</td>
<td>24</td>
<td>7</td>
<td>Generalised</td>
<td>Sneezing, barking, grunting</td>
<td>Turning, self injury</td>
<td>None</td>
<td>Echolalia, coprolalia</td>
</tr>
<tr>
<td>9 M</td>
<td>26</td>
<td>5</td>
<td>Head</td>
<td>Coughing, sneezing</td>
<td>None</td>
<td>None</td>
<td>Echolalia, coprolalia</td>
</tr>
<tr>
<td>10 M</td>
<td>44</td>
<td>10</td>
<td>Head</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

**Table 2 Details of patients with Tourette’s syndrome studied with **11C-raclopride PET**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Onset (y)</th>
<th>Simple tics</th>
<th>Complex tics</th>
<th>Obsessions/compulsions</th>
<th>Drugs*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Motor</td>
<td>Vocal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1† M</td>
<td>26</td>
<td>5</td>
<td>Head</td>
<td>Coughing, sneezing</td>
<td>None</td>
<td>Coprolalia, Echolalia</td>
<td>Counting rituals</td>
</tr>
<tr>
<td>2 M</td>
<td>46</td>
<td>10</td>
<td>Face</td>
<td>Sniffing, grunting, coughing</td>
<td>Touching self</td>
<td>Coprolalia</td>
<td>Complex rituals, checking</td>
</tr>
<tr>
<td>3 M</td>
<td>18</td>
<td>8</td>
<td>Head</td>
<td>Sniffing, whistling, sneezing</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>4 M</td>
<td>37</td>
<td>5</td>
<td>Generalised</td>
<td>Throat clearing, grunting, barking</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>5 M</td>
<td>39</td>
<td>12</td>
<td>Generalised</td>
<td>Coughing, grunting</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*At the time of the scan.
†Patient previously studied with **18F-dopa PET (number 9).
MBq of tracer in 5 ml of normal saline (mean specific activity: 19 072 MBq/μmol) was injected as a bolus. Scanning began after a 30 second background frame, with collection of 22 serial time frames, increasing from five seconds to 10 minutes duration over a 60 minute study period.

DATA ANALYSIS
Image analysis was performed with Analyze software (version 5.0-1, BRU, Mayo Foundation, Rochester, MN, USA), on SUN Sparc2 computer workstations. Regions of interest were defined by inspection of an image of integrated tracer activity. This image contained the activity collected from 30–94 minutes for 18F-dopa scans and from 20–60 minutes for 11C-raclopride scans. Regions of interest were placed with a standard template arrangement as previously reported. Regional time activity plots were then obtained for each region by projecting these regions of interest on the dynamic time frames.

18F-dopa—The data were analysed with a modified multiple time graphical analysis approach, with the occipital lobe as a non-specific tissue reference input function. This method generates influx constants (K, values), for both caudate and putamen. The K, value is an influx constant that reflects the uptake and subsequent metabolism of 18F-dopa by the nigrostriatal terminals and therefore reflects the functional integrity of the dopaminergic projections.

11C-raclopride—Regional time activity curves were analysed with a reference tissue model with cerebellar input as described elsewhere. This method provides estimates of the binding potential of caudate and putamen, a measure of the number of available D2 receptors. Mean striatal 18F-dopa K, values and 11C-raclopride binding potentials for each group were compared by Student's unpaired t statistics, with a Bonferroni correction for multiple comparisons (n = 10).

Results
Some patients exhibited tics during PET, but this did not lead to any significant degradation of the images.

18F-dopa PET
The mean values for caudate and putamen 18F-dopa influx constants were similar in patients with Tourette's syndrome and controls. All individual patient caudate and putamen K, values were within two SDs of the normal mean (fig 1). The Tourette's syndrome K, values were also similar to the subgroup of age matched normal controls (mean normal caudate: 0.0098 (0.0011), putamen: 0.0093 (0.0009) min−1). There were no differences in striatal 18F-dopa K, values between treated and untreated Tourette's syndrome.

11C-raclopride PET
The mean caudate and putamen binding potentials in Tourette's syndrome were similar to control values. Figure 2 shows individual caudate and putamen binding potentials for Tourette's syndrome and control subjects. All except one lay within two SDs of the normal means. When the patients with Tourette's syndrome were compared with a smaller subgroup of five age matched normal controls, mean binding potentials of both groups remained similar (mean normal caudate: 2.36 (0.19) and putamen: 2.45 (0.07)).

Discussion
Our nine patients with Tourette's syndrome and one patient with multiple tic disease studied with 18F-dopa PET all had normal uptake and storage of this tracer in their nigrostriatal dopaminergic terminals. A further group of five patients with Tourette's syndrome studied with 11C-raclopride exhibited normal postsynaptic striatal D2 receptor binding potentials.
PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome

As seven of the 10 patients scanned with 18F-dopa were receiving chronic neuroleptic treatment at the time of PET it is necessary to consider the effects of these drugs on the activity of aromatic amino acid decarboxylase, the enzyme in the dopaminergic terminals responsible for decarboxylating exogenous 18F-dopa. The effects of chronic treatment on the dopaminergic presynaptic projections are well established; however, the effects of chronic treatment are still uncertain. Studies on rats have shown increased release of striatal dopamine, and increased aromatic amino acid decarboxylase activity, after acute challenges with dopamine D1 and D2 antagonists. Chronic haloperidol treatment decreased basal dopamine release, although we have been unable to find data about its effect on aromatic amino acid decarboxylase activity. Our own preliminary experiments suggest that such activity may become mildly raised in the rat striatum (Opacka-Juffry, personal communication). This could lead to a slight increase in striatal 18F-dopa uptake, although none was evident in our Tourette's syndrome group.

Decreased concentrations of the dopamine metabolite homovanillic acid and the serotonin metabolite 5-hydroxyindoleacetic acid have been reported in the CSF of patients with Tourette's syndrome. Postmortem studies with [3H]mazindol, have suggested increased dopaminergic reuptake site density (37% in caudate and 50% in putamen) in patients with Tourette's syndrome. Concentrations of dopamine and its metabolites in the striatum were, however, normal. The striatal concentration of adenosine 3',5'-monophosphate (cyclic AMP) has also been reported to be reduced in four patients with Tourette's syndrome. In the light of these findings, it has been postulated that the primary defect in Tourette's syndrome could be abnormal dopamine turnover within the striatum, or abnormal second messenger production. In our 18F-dopa PET study all patients with Tourette's syndrome had caudate and putamen influx constants within two SDs of the normal mean. Consequently, our PET findings do not support the presence of a primary dysfunction of dopa metabolism in the presynaptic dopaminergic terminals.

Rituals and obsessive behaviour were a clinical feature in nine of our 10 patients studied with 18F-dopa. Our results are in agreement with a previous 18F-dopa study that reported normal striatal tracer uptake in patients with obsessive slowness. Singer and coworkers found normal striatal D1 and D2 receptor density in Tourette's syndrome postmortem studies. Wong and colleagues, in a preliminary 11C-methylspiperone PET study, detected increased D2 receptor density in four patients with Tourette's syndrome. More recently, the same group reported caudate/cerebellar ratios in 19 patients with Tourette's syndrome and found no group differences although the results were compared with controls, although there was increased variance in patient values. Our findings of normal striatal D2 site binding in four out of five patients with Tourette's syndrome studied with 11C-raclopride are in accordance with the above report.

Metabolic PET studies in patients with Tourette's syndrome under resting condition have shown acute neuroleptic treatment with D, and spiperone PET colleagues, normal striatal concentration of adenosine 3',5'-monophosphate in association with improvement of both tics and obsessive-compulsive syndrome. In conclusion, using 18F-dopa and 11C-raclopride PET, we have been unable to find any abnormality of dopamine metabolism and storage in the nigrostriatal dopaminergic terminals, or in the density of striatal postsynaptic D2 receptors in patients with Tourette's syndrome. Our findings, however, do not exclude a dysfunction of endogenous dopamine production, or altered proportions of D2 receptors in high and low agonist affinity conformations in this condition.

We thank colleagues of the Chemistry and PET methods section at the MRC Cyclotron Unit for their expert assistance, and also Mrs A Williams, Ms CTV Taylor, and Mr GC Lewington for their help with scanning.

10 Goetz CG, Tanner CM. Gilles de la Tourette's syndrome.
NEUROLOGICAL STAMP

François Magendie (1783–1855)

François Magendie, born in Bordeaux in 1783, was appointed Professor of Medicine at the College de France in Paris in 1831. He made important discoveries in neurophysiology and nutrition and is regarded by some as the father of experimental pharmacology. He is best remembered for his work on the cerebrospinal fluid and the canal in the brain that bears his name. One of his most important contributions was proof (in a litter of puppies) that the anterior roots of the spinal nerve were motor and the posterior sensory. A bitter dispute over the priority for the discovery ensued with the distinguished physiologist Charles Bell.

Magendie was also the first to produce decerebrate rigidity, the effects of excision or section of the cerebellum and of “circus movement” resulting from a lesion of the optic thalamus.

His investigations in pharmacology introduced bromine, quinine, emetine, and morphine into medical practice and he showed the effect of strychnine on the paralysed spinal cord. His Formulare was published in 1821.

In 1815, post-revolutionary France was short of food. Magendie was appointed Chairman of a Commission to investigate the nutritional value of various food extracts. He showed the need for adequate amounts of the right sort of protein in a diet, laying the foundations for the science of nutrition. In 1842 he published an influential book that helped to reform clinical medicine along physiological lines.

He died on his birthday in 1855 and was honoured in 1985 in the Heroes of Medicine series issued by the Republic of Transkei. (Stanley Gibbons 178).

L F HAAS
PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.

N Turjanski, G V Sawle, E D Playford, R Weeks, A A Lammerstma, A J Lees and D J Brooks

*J Neurol Neurosurg Psychiatry* 1994 57: 688-692

doi: 10.1136/jnnp.57.6.688

Updated information and services can be found at:

[http://jnnp.bmj.com/content/57/6/688](http://jnnp.bmj.com/content/57/6/688)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:

[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:

[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:

[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)